conference call 11pm 31/3/14, page-4

Conference call just finished, on the Line Geoffrey Kempler, Diane Angus, Prof Rudy Tanzi, Prof Ira Shoulson.
Gist seemed to me:

Disappointment with results, but seemed to be a sense that the method of detection PIB-Pet may not have been the best choice (MRI more effective), and also that the focus on reduction of ameloid, should instead have been on improvement of Executive function.
A sense that the small size of the group, both treatment and placebo, led to variations that were incompatible with finding a statistical benefit. Ie Ameloid was observed reduce in both Treatment and Placebo group.
Going forward, company still staying positive. Focusing on commercialization of PBT2 for Huntington Disease, using the Orphan Drug Status (2016.2017)
Any further Alzhiemer trial would need to be larger, and this would require some partnership with a Pharma Company.

My brief summary, the recording should be available in an hour or so.